Introduction: Oral anticoagulant is essential for the treatment and prevention of thromboembolism. Warfarin is an effective oral anticoagulant in prevention and treatment of thromboembolism. However, warfarin is frequently associated with adverse event (AE) requiring hospitalization. Method: We performed a retrospective cohort study of all patients admitted to a large tertiary public hospital for warfarin-related AEs. Patients were grouped based on bleeding severity and the direct medical cost was also calculated. Results: During the 4 years study period, a total of 224 patients were admitted for warfarin-related AEs. Mean age of patients admitted was 65.1 years (standard deviation [SD] = 11.5). More than half, 59.6%, of them were on warfarin for prevention of stroke in atrial fibrillation or atrial flutter. Major bleeding occurred among 50.9% of the patients with gastrointestinal bleed, 34 (29.8%), as the common site of bleed. Patients with major bleed had longer median hospital stay of 4 days (interquartile range [IQR] = 5) compared to 3 (IQR = 3) days in non-major bleed. There were 17 (14.9%) death among the major bleeders. Mean medical cost for managing warfarin-related AEs was USD 708.08. Conclusion: The admitted patients were equally distributed in terms of bleeding severity. Medical cost incurred for managing warfarin-related AEs increased with the severity of bleeding.
Introduction: Oral anticoagulant is essential for the treatment and prevention of thromboembolism. Warfarin is an effective oral anticoagulant in prevention and treatment of thromboembolism. However, warfarin is frequently associated with adverse event (AE) requiring hospitalization. Method: We performed a retrospective cohort study of all patients admitted to a large tertiary public hospital for warfarin-related AEs. Patients were grouped based on bleeding severity and the direct medical cost was also calculated. Results: During the 4 years study period, a total of 224 patients were admitted for warfarin-related AEs. Mean age of patients admitted was 65.1 years (standard deviation [SD] = 11.5). More than half, 59.6%, of them were on warfarin for prevention of stroke in atrial fibrillation or atrial flutter. Major bleeding occurred among 50.9% of the patients with gastrointestinal bleed, 34 (29.8%), as the common site of bleed. Patients with major bleed had longer median hospital stay of 4 days (interquartile range [IQR] = 5) compared to 3 (IQR = 3) days in non-major bleed. There were 17 (14.9%) death among the major bleeders. Mean medical cost for managing warfarin-related AEs was USD 708.08. Conclusion: The admitted patients were equally distributed in terms of bleeding severity. Medical cost incurred for managing warfarin-related AEs increased with the severity of bleeding.
Authors: Yan Xu; Sam Schulman; Dar Dowlatshahi; Anne M Holbrook; Christopher S Simpson; Lois E Shepherd; Philip S Wells; Antonio Giulivi; Tara Gomes; Muhammad Mamdani; Eliot Frymire; Shahriar Khan; Ana P Johnson Journal: Thromb Res Date: 2019-08-02 Impact factor: 3.944
Authors: Jennifer Hollowell; Ana Ruigómez; Saga Johansson; Mari-Ann Wallander; Luis Alberto García-Rodríguez Journal: Br J Gen Pract Date: 2003-04 Impact factor: 5.386
Authors: Nita A Limdi; T Mark Beasley; Melissa F Baird; Joyce A Goldstein; Gerald McGwin; Donna K Arnett; Ronald T Acton; Michael Allon Journal: J Am Soc Nephrol Date: 2009-02-18 Impact factor: 10.121
Authors: Albert Yuh-Jer Shen; Janis F Yao; Somjot S Brar; Michael B Jorgensen; Wansu Chen Journal: J Am Coll Cardiol Date: 2007-07-06 Impact factor: 24.094
Authors: Mustafa Ozturk; Afsin Ipekci; Sevil Kusku Kiyak; Yonca Sinem Akdeniz; Yavuz Aydin; Ibrahim Ikizceli; Ozgur Sogut Journal: J Clin Med Res Date: 2019-01-05